Geftinat

Geftinat 250 mg (Gefitinib) is specified against a type of lung cancer (non-small cell) wherein cells are mutated in epidermal growth factor receptor (EGFR). EGFR is expressed on the cell surface of these cancerous cells. Geftinat 250 mg (Gefitinib) selectively targets the proteins that are mutated in these cells. It is taken orally as a 250 mg dose once daily with or without food.

Additional properties of Geftinat 250 mg (Gefitinib):

Once Geftinat 250 mg (Gefitinib) enters our system, it takes around 3 to 7 hours for absorbing at least 60% of the drug. With 90% binding affinity with cancerous cells, Gefitinib carries out anti-cancer activities by metabolizing in the liver. Finally, more than 50% of the drug gets excreted out of the system within 2 days.

Modifications in dosing based on the side-effects:

Note: Patients can resume Gefitinib after the side-effects vanish.

Other warnings before taking Gefitinib:

The healthcare provider should be notified regarding,

• Lung or breathing problems
• Liver complications
• Difficulties in visualizing
• Pregnancy
• Breastfeeding
• Proton pump inhibitors, antacids or other medicines

Most common side-effects:

• Diarrhea
• Skin reactions (rashes, dry skin and itching)
• Sickness
• Ulcers on the mouth
• Loss of appetite

Note: These are not all side-effects of Gefitinib, inform your healthcare provider if you witness others.